1-溴-4-氟-2-异丙氧基苯 | 610797-49-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-溴-4-氟-2-异丙氧基苯
• 英文名称: 1-bromo-4-fluoro-2-isopropoxybenzene
• 英文别名: 1-bromo-2-isopropoxy-4-fluoro-benzene；1-bromo-4-fluoro-2-isopropoxy-benzene；1-bromo-4-fluoro-2-propan-2-yloxybenzene
• CAS: 610797-49-4
• 化学式: C₉H₁₀BrFO
• 分子量: 233.08
• InChiKey: OJWUXVJGCPUWTK-UHFFFAOYSA-N

物化性质

• 沸点：
  221.8±20.0 °C(Predicted)
• 密度：
  1.393±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2909309090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Bromo-4-fluoro-2-isopropoxybenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Bromo-4-fluoro-2-isopropoxybenzene
CAS number: 610797-49-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H10BrFO
Molecular weight: 233.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-溴-4-氟-2-异丙氧基苯 在 palladium on activated charcoal 正丁基锂 、 氢气 、 三乙酰氧基硼氢化钠 、 sodium carbonate 、 溶剂黄146 、 甲基磺酰氯 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， -78.0~20.0 ℃ 、310.27 kPa 条件下， 反应 44.0h， 生成 N-trans-{4-[4-(4-fluoro-2-isopropoxy-phenyl)-piperidin-1-yl]-cyclohexyl}-3,4-dimethoxy-benzenesulfonamide
  参考文献：
  名称：

  (Phenylpiperidinyl)cyclohexylsulfonamides: Development of α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)

  摘要：

  Although alpha(1), adrenergic receptor blockers can be very effective for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), their usage is limited by CV-related side-effects that are caused by the subtype non-selective nature of the current drugs. To overcome this problem, it was hypothesized that a alpha(1a/1d) subtype selective antagonist would bring more benefit for the therapy of BPH/LUTS. In developing such selective alpha(1a/1d) ligands, a series of (phenylpiperidinyl)cyclohexylsulfonamides has been synthesized and evaluated for binding to three cloned human alpha(1)-adrenergic receptor subtypes. Many compounds showed equal affinity for both alpha(1a) and alpha(1d) subtypes with good selectivity versus the alpha(1b) subtype. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.098
• 作为产物：
  描述：

  2-碘代丙烷 、 2-溴-5-氟苯酚 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 以95%的产率得到1-溴-4-氟-2-异丙氧基苯
  参考文献：
  名称：

  Piperidinyl substituted cyclohexane-1,4-diamines

  摘要：

  本发明涉及式(I)的哌啶取代的环己烷-1,4-二胺化合物及其药学上可接受的形式，作为α1a/α1d肾上腺素受体调节剂，用于治疗良性前列腺肥大和下尿路症状。本发明还涉及包含所述新化合物的药物组合物，制备这些新化合物的新方法以及作为药物的新用途和治疗方法。

  公开号：

  US20060217419A1

文献信息

• Piperidinyl substituted cyclohexane-1,4-diamines
  申请人：Chiu George

  公开号：US20060217419A1

  公开（公告）日：2006-09-28

  The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α 1a /α 1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.

  本发明涉及式(I)的哌啶取代的环己烷-1,4-二胺化合物及其药学上可接受的形式，作为α1a/α1d肾上腺素受体调节剂，用于治疗良性前列腺肥大和下尿路症状。本发明还涉及包含所述新化合物的药物组合物，制备这些新化合物的新方法以及作为药物的新用途和治疗方法。
• Regioselective SNAr reactions of substituted difluorobenzene derivatives: practical synthesis of fluoroaryl ethers and substituted resorcinols
  作者：Stéphane G. Ouellet、Anna Bernardi、Remy Angelaud、Paul D. O’Shea

  DOI：10.1016/j.tetlet.2009.03.204

  日期：2009.7

  In this Letter, we describe a practical and highly selective method for the preparation of fluoroaryl ethers and differentially substituted resorcinol derivatives. This synthetic strategy relies on a selective SNAr of substituted difluorobenzene derivatives with various alcohols.

  在这封信中，我们描述了一种实用且高度选择性的方法，用于制备氟代芳基醚和差异取代的间苯二酚衍生物。该合成策略依赖于取代的二氟苯衍生物与各种醇的选择性S N Ar。
• Ruthenium olefin metathesis catalysts with modified styrene ethers: influence of steric and electronic effects
  作者：Mirko Zaja、Stephen J Connon、Aideen M Dunne、Michael Rivard、Nicole Buschmann、Jan Jiricek、Siegfried Blechert

  DOI：10.1016/s0040-4020(03)01029-9

  日期：2003.8

  A series of olefin metathesis catalysts with modified isopropoxybenzylidene ligands were synthesised, and the effects of ligands on the rate of metathesis investigated. Increased steric hinderance ortho to the isopropoxy group enhanced reaction rates. In the case of N-heterocyclic carbene complexes, decreasing electron density at both the chelating oxygen atom and the RuC bond accelerated reaction

  合成了一系列具有修饰的异丙氧基亚苄基配体的烯烃复分解催化剂，并研究了配体对复分解速率的影响。与异丙氧基相邻的位阻增加，反应速率提高。在N-杂环卡宾配合物的情况下，在螯合氧原子和RuC键上电子密度的降低明显地促进了反应速率。含有三环己基膦配体的催化剂在亚苄基亲电性方面遵循相同的趋势，而在氧气下较高的电子密度提高了反应速率。
• [EN] SELECTIVE ESTROGEN RECEPTOR MODULATORS<br/>[FR] MODULATEURS SELECTIFS DU RECEPTEUR DES OESTROGENES
  申请人：LILLY CO ELI

  公开号：WO2005073244A1

  公开（公告）日：2005-08-11

  The present invention relates to a selective estrogen receptor modulator of formula I: I; or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma. X16065 PCT - -

  本发明涉及公式I的选择性雌激素受体调节剂：I；或其药物酸盐；例如用于治疗子宫内膜异位症和子宫肌瘤。X16065 PCT。
• Selective Estrogen Receptor Modulators
  申请人：Dodge Jeffrey Alan

  公开号：US20080221163A1

  公开（公告）日：2008-09-11

  The present invention relates to a selective estrogen receptor modulator of formula I: I; or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.

  本发明涉及一种式子I的选择性雌激素受体调节剂: I; 或其药物酸加盐，可用于治疗子宫内膜异位症和子宫平滑肌瘤等疾病。